Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

DDX41 Dissolves G-Quadruplexes to Maintain Erythroid Genomic Integrity and Prevent Genome DNA Leakage-Induced Cgas Activation

Honghao Bi, Pan Wang, Wen Wang, Kehan Ren, Elizabeth Bartom, Xu Han, Ermin Li, Peng Ji

Blood (2023) 142 (Supplement 1): 949.

https://doi.org/10.1182/blood-2023-177765

Published: 2023

Journal Articles

Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Equecabtagene Autoleucel (Eque-cel, CT103A) in Fumanba-1

Chunrui Li, Lu-Gui Qiu, Di Wang, Yongping Song, He Huang, Jianyong Li, Bing Chen, Jing Liu, Yujun Dong, Kai Hu, Peng Liu, Xi Zhang, Jianqing Mi, Zhenyu Li, Kaiyang Ding, Shiyue Zhang, Guang Hu, Wen Wang

Blood (2023) 142 (Supplement 1): 761.

https://doi.org/10.1182/blood-2023-173427

Published: 2023

Journal Articles

Single Cell Correlation Analysis: A Novel Method to Analyze Single Cell RNA Sequencing Data Identifies a Self-Renewing Subpopulation of Human Acute Myeloid Leukemia Stem Cells

Yoonkyu Lee, Wen Wang, Timothy K Starr, Klara E Noble-Orcutt, Chad L Myers, Zohar Sachs

Blood (2023) 142 (Supplement 1): 241.

https://doi.org/10.1182/blood-2023-186606

Published: 2023

Journal Articles

A Prediction Model for Early Recurrence after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with CMML: A Nationwide Representative Multicenter Study

Blood (2023) 142 (Supplement 1): 4951.

https://doi.org/10.1182/blood-2023-184407

Published: 2023

Journal Articles

Long-Term Follow-up of Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple Myeloma

Chunrui Li, Di Wang, Qiuxia Yu, Zhe Li, Wen Wang, Guang Hu, Wei Mu, Chunhui Li, Ning An, Xiaolu Long, Yuhan Bao

Blood (2023) 142 (Supplement 1): 4854.

https://doi.org/10.1182/blood-2023-181394

Published: 2023

Journal Articles

Updated Results of Fumanba-1: A Phase 1b/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma

Blood (2022) 140 (Supplement 1): 7435–7436.

https://doi.org/10.1182/blood-2022-166465

Published: 2022

Journal Articles

All- trans retinoic acid plus low-dose rituximab vs low-dose rituximab in corticosteroid-resistant or relapsed ITP

Ye-Jun Wu, Hui Liu, Qiao-Zhu Zeng, Yi Liu, Jing-Wen Wang, Wen-Sheng Wang, Jia-Feng, He-Bing Zhou, Qiu-Sha Huang, Yun He, Hai-Xia Fu, Xiao-Lu Zhu, Qian Jiang, Hao Jiang, Ying-Jun Chang, Lan-Ping Xu, Xiao-Jun Huang, Xiao-Hui Zhang

Blood (2022) 139 (3): 333–342.

https://doi.org/10.1182/blood.2021013393

Published: 2022

Includes: Supplemental data

Journal Articles

Pomalidomide Promotes the Maturation of Healthy Donors and Multiple Myeloma Patients Derived-Dendritic Cells

Xi Wang, Feifei Che, Wanjun Cao, Zichen Ye, Hong Zheng, Xiaobing Huang, Rong Xiao, Wen Wang, Xuemei Ye, Lin He, Jingying Dai

Blood (2021) 138 (Supplement 1): 4702.

https://doi.org/10.1182/blood-2021-146768

Published: 2021

Journal Articles

All-Trans Retinoic Acid Plus Low-Dose Rituximab Vs Low-Dose Rituximab in Corticosteroid-Resistant or Relapsed ITP

Ye-Jun Wu, Hui Liu, Qiao-Zhu Zeng, Yi Liu, Jing-Wen Wang, Wen-Sheng Wang, Jia Feng, He-Bing Zhou, Qiu-Sha Huang, Hai-Xia Fu, Xiao-Lu Zhu, Yun He, Hao Jiang, Ying-Jun Chang, Lan-Ping Xu, Xiao-Jun Huang, Xiao-Hui Zhang

Blood (2021) 138 (Supplement 1): 15.

https://doi.org/10.1182/blood-2021-149527

Published: 2021

Journal Articles

A Phase 1/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 547.

https://doi.org/10.1182/blood-2021-152576

Published: 2021

Journal Articles

A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma

Blood (2021) 137 (21): 2890–2901.

https://doi.org/10.1182/blood.2020008936

Published: 2021

Includes: Supplemental data

Journal Articles

Smarca5-mediated epigenetic programming facilitates fetal HSPC development in vertebrates

Yanyan Ding, Wen Wang, Dongyuan Ma, Guixian Liang, Zhixin Kang, Yuanyuan Xue, Yifan Zhang, Lu Wang, Jian Heng, Yong Zhang, Feng Liu

Blood (2021) 137 (2): 190–202.

https://doi.org/10.1182/blood.2020005219

Published: 2021

Includes: Supplemental data

Journal Articles

Stemness Signature Defined By Logistic Regression Machine Learning and Artificial Intelligence Predicts Outcomes in Diffuse Large B-Cell Lymphoma

Xiao-jie Liang, Na Yao, Dan Liu, Hai-ying Chen, Xin Xu, Jing-Wen Wang, Ken H. Young, Liang Wang

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-141791

Published: 2020

Journal Articles

Polatuzumab Vedotin-Based Salvage Chemotherapy in the Third-Line or Above Treatment for Diffuse Large B-Cell Lymphoma

Cheng-Hong Tsai, MD MSc, Feng Ming Tien, MD MSc, Hsin-An Hou, MD PhD, Jia-Hau Liu, MD, Shang-Ju Wu, MD PhD, Yu-Wen Wang, MSc., Chien-Chin Lin, MD, Bor-Sheng Ko, MD PhD, Wen-Chien Chou, MD PhD, Yun-Chu Lin, MD, Chieh-Lung Cheng, MD, Li-Chun Lu, MD PhD, Sung-Hsin Kuo, MD PhD, Ruey-Long Hong, MD PhD, Tai-Chung Huang, MD PhD, Ming Yao, MD

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-138481

Published: 2020

Journal Articles

Combined Single Cell Lineage and Transcriptome Sequencing Unveils Cell-Autonomous Regulators of Hematopoietic Stem Cell Fate

Alejo E Rodriguez-Fraticelli, PhD, Caleb S Weinreb, PhD, Allon Moshe Klein, PhD, Shou-Wen Wang, PhD, Fernando D Camargo, PhD

Blood (2019) 134 (Supplement_1): 446.

https://doi.org/10.1182/blood-2019-123447

Published: 2019

Journal Articles

Cellular Kinetics and Anti-Therapeutic Antibody in Relapsed/Refractory B-NHL Patients Treated with JWCAR029

Zhitao Ying, MD PhD, Pengpeng Xu, MD, Ming Hao, PhD, Li Wang, MD PhD, Shu Cheng, MD PhD, Wen Wu, MD PhD, Wen Wang, MD PhD, Zisong Zhou, Su Yang, Jennifer Wang, PhD, Harry Lam, PhD, James Li, Hongxia Zheng, MD PhD, Weili Zhao, MD PhD, Yuqin Song, MD PhD, Jun Zhu, BS

Blood (2019) 134 (Supplement_1): 4083.

https://doi.org/10.1182/blood-2019-126408

Published: 2019

Journal Articles

Clinical Response in Relapsed/Refractory (R/R) B-NHL Treated with the CD19-Directed CAR T-Cell Product JWCAR029

Zhitao Ying, MD PhD, Pengpeng Xu, MD, Li Wang, MD PhD, Shu Cheng, MD PhD, Wen Wu, MD PhD, Wen Wang, MD PhD, Ming Hao, PhD, Su Yang, Harry Lam, PhD, James Li, Hongxia Zheng, MD PhD, Weili Zhao, MD PhD, Yuqin Song, MD PhD, Jun Zhu, BS

Blood (2019) 134 (Supplement_1): 2876.

https://doi.org/10.1182/blood-2019-127751

Published: 2019

Journal Articles

Combination of ATRA and High-Dose Dexamethasone As First-Line Treatment in Adult Immune Thrombocytopenia:a Randomized, Phase 2, Open-Label Trial

Qiu-Sha Huang, Yi Liu, Jing-Bo Wang, Jun Peng, Ming Hou, Hui Liu, Jing-Wen Wang, Lan-Ping Xu, Kaiyan Liu, Xiao-Jun Huang, MD, Xiao-Hui Zhang

Blood (2019) 134 (Supplement_1): 899.

https://doi.org/10.1182/blood-2019-125242

Published: 2019

Journal Articles

Efficacy and Safety of JWCAR029 in Adult Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Zixun Yan, Wen Wang, MD, Zhong Zheng, Ming Hao, Su Yang, James Li, Shu Cheng, Li Wang, Wei-li Zhao

Blood (2018) 132 (Supplement 1): 4187.

https://doi.org/10.1182/blood-2018-99-115769

Published: 2018

Journal Articles

JWCAR029 Is a CD19-Targeted CAR T Cell Product with Process and Quality Controls Delivered As a Flat Dose of CAR T Cell to Patients with NHL

Wen Wang, MD, Ming Hao, Yin Cheng, PhD, Juan Gao, MSc, Su Yang, Yanwei Liu, BSc, Harry Lam, PhD, Shuyuan Yao, PhD, James Li

Blood (2018) 132 (Supplement 1): 5387.

https://doi.org/10.1182/blood-2018-99-114434

Published: 2018

NARROW

DDX41 Dissolves G-Quadruplexes to Maintain Erythroid Genomic Integrity and Prevent Genome DNA Leakage-Induced Cgas Activation

Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Equecabtagene Autoleucel (Eque-cel, CT103A) in Fumanba-1

Single Cell Correlation Analysis: A Novel Method to Analyze Single Cell RNA Sequencing Data Identifies a Self-Renewing Subpopulation of Human Acute Myeloid Leukemia Stem Cells

A Prediction Model for Early Recurrence after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with CMML: A Nationwide Representative Multicenter Study

Long-Term Follow-up of Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple Myeloma

Updated Results of Fumanba-1: A Phase 1b/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma

All- trans retinoic acid plus low-dose rituximab vs low-dose rituximab in corticosteroid-resistant or relapsed ITP

Pomalidomide Promotes the Maturation of Healthy Donors and Multiple Myeloma Patients Derived-Dendritic Cells

All-Trans Retinoic Acid Plus Low-Dose Rituximab Vs Low-Dose Rituximab in Corticosteroid-Resistant or Relapsed ITP

A Phase 1/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma

A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma

Smarca5-mediated epigenetic programming facilitates fetal HSPC development in vertebrates

Stemness Signature Defined By Logistic Regression Machine Learning and Artificial Intelligence Predicts Outcomes in Diffuse Large B-Cell Lymphoma

Polatuzumab Vedotin-Based Salvage Chemotherapy in the Third-Line or Above Treatment for Diffuse Large B-Cell Lymphoma

Combined Single Cell Lineage and Transcriptome Sequencing Unveils Cell-Autonomous Regulators of Hematopoietic Stem Cell Fate

Cellular Kinetics and Anti-Therapeutic Antibody in Relapsed/Refractory B-NHL Patients Treated with JWCAR029

Clinical Response in Relapsed/Refractory (R/R) B-NHL Treated with the CD19-Directed CAR T-Cell Product JWCAR029

Combination of ATRA and High-Dose Dexamethasone As First-Line Treatment in Adult Immune Thrombocytopenia:a Randomized, Phase 2, Open-Label Trial

Efficacy and Safety of JWCAR029 in Adult Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

JWCAR029 Is a CD19-Targeted CAR T Cell Product with Process and Quality Controls Delivered As a Flat Dose of CAR T Cell to Patients with NHL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only